Key points are not available for this paper at this time.
is capable of selectively delivering its drug-like, small-molecule cargo to AML cells in vitro and in a localized tumor model in an HOCl-gated manner. In the long term, we envision the potential use of this technology to afford HOCl-gated delivery systems with selectivity toward HOCl-positive AML cells. More broadly, this approach provides a potentially generalizable strategy for the development of simplified theranostic agents targeted toward small-molecule analytes and enzymatic activities associated with disease.
Yuan et al. (2025) studied this question.